Partial-onset Seizures
📧 Sign up to get email alerts when something new happens for Partial-onset Seizures.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-02-18FDA Approved: BRIVIACT — Original Application (UCB, Inc.)
FDA approved Briviact (brivaracetam) based on UCB, Inc.'s original NDA, establishing it as an adjunctive therapy for partial-onset seizures …
-
FDA approval · 2016-02-18FDA Approved: BRIVIACT — Original Application (UCB, Inc.)
The FDA approved Briviact (brivaracetam) as an adjunctive treatment for partial-onset seizures in adults and in children aged 4 years and ol…
-
FDA approval · 2016-02-18FDA Approved: BRIVIACT — Original Application (UCB, Inc.)
FDA approved Briviact (brivaracetam) under its original application by UCB, Inc. for adjunctive treatment of partial-onset seizures in epile…
-
CLINICAL_TRIALS trial_result · 2016-02-12Clinical Trial Update: Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures [Phase 4]
A Phase 4 trial compared adjunctive levetiracetam to topiramate in adults with refractory partial-onset seizures. The study is completed and…
-
FDA approval · 2016-02-01FDA Approved: LEVETIRACETAM — Original Application (Eugia US LLC)
The FDA approved an Abbreviated New Drug Application (ANDA) for levetiracetam from Eugia US LLC, authorizing the marketing of a generic vers…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-01-26Clinical Trial Update: Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures [Phase 3]
Phase 3 trial update evaluating adjunctive perampanel (E2007) for refractory partial seizures in epilepsy; results were posted in 2016.
-
FDA approval · 2016-01-06FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)
The FDA approved a supplemental application for APTIOM (eslicarbazepine acetate) submitted by Sumitomo Pharma America, Inc. The approval per…
-
CLINICAL_TRIALS trial_result · 2015-12-21Clinical Trial Update: Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic [Phase 3]
Phase 3 trial evaluating safety and efficacy of eslicarbazepine monotherapy in patients with partial epilepsy not well controlled by current…
-
FDA approval · 2015-12-14FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
FDA approved Eisai's supplemental application for FYCOMPA (perampanel) to update the labeling and potentially expand its approved uses for e…
-
FDA approval · 2015-12-14FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for Levetiracetam from Prasco Laboratories, resulting in updated labeling for this antiepileptic…
-
FDA approval · 2015-12-04FDA Approved: OXTELLAR XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
FDA approved a supplemental application for OXTELLAR XR (oxcarbazepine) submitted by Supernus Pharmaceuticals, indicating an approved update…
-
CLINICAL_TRIALS trial_result · 2015-12-04Clinical Trial Update: Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures [Phase 3]
An open-label Phase 3 study evaluated the safety and tolerability of intravenous lacosamide in Japanese adults with partial-onset seizures; …
-
FDA approval · 2015-10-02FDA Approved: LEVETIRACETAM — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals LLC's supplemental application for levetiracetam, a generic form of the antiepileptic drug, under up…
-
FDA approval · 2015-09-10FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)
FDA approved a supplemental application for APTIOM (eslicarbazepine acetate) from Sumitomo Pharma America, Inc., signaling an update to the …
-
CLINICAL_TRIALS trial_result · 2015-08-19Clinical Trial Update: A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)
Post-marketing study evaluating eslicarbazepine acetate as an adjunctive treatment for partial-onset seizures; the EPOS trial (E2093-E044-40…
-
FDA approval · 2015-08-13FDA Approved: LEVETIRACETAM — Original Application (Fresenius Kabi USA, LLC)
The FDA approved Fresenius Kabi USA, LLC's generic levetiracetam, expanding access to an anticonvulsant used to treat various seizure disord…
-
FDA approval · 2015-07-09FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a Supplemental Application for VIMPAT (lacosamide) filed by UCB, Inc.
-
FDA approval · 2015-07-09FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) filed by UCB, Inc.
-
FDA approval · 2015-06-19FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
The FDA approved a supplemental application for FYCOMPA (perampanel) from Eisai Inc., resulting in an updated labeling for the drug.
-
FDA approval · 2015-06-19FDA Approved: ZONEGRAN — Supplemental Application (Advanz Pharma (US) Corp.)
FDA approved a supplemental application for Zonegran (zonisamide) from Advanz Pharma (US) Corp.
-
FDA approval · 2015-06-13FDA Approved: ZONISAMIDE — Supplemental Application (Exelan Pharmaceuticals, Inc.)
FDA approved a supplemental application for Zonisamide submitted by Exelan Pharmaceuticals, Inc. under ANDA 077869.
-
FDA approval · 2015-06-11FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)
FDA has approved a Supplemental Application for APTIOM (eslicarbazepine acetate) from Sumitomo Pharma America, expanding labeling/indication…
-
FDA approval · 2015-06-04FDA Approved: LEVETIRACETAM — Original Application (Major Pharmaceuticals)
FDA approved the Original Application for levetiracetam from Major Pharmaceuticals, making a generic version of the anticonvulsant available…
-
FDA approval · 2015-04-15FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc.
-
FDA approval · 2015-04-14FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) filed by Novartis Pharmaceuticals Corporation.